584 related articles for article (PubMed ID: 30808634)
1. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.
Karschnia P; Jordan JT; Forst DA; Arrillaga-Romany IC; Batchelor TT; Baehring JM; Clement NF; Gonzalez Castro LN; Herlopian A; Maus MV; Schwaiblmair MH; Soumerai JD; Takvorian RW; Hochberg EP; Barnes JA; Abramson JS; Frigault MJ; Dietrich J
Blood; 2019 May; 133(20):2212-2221. PubMed ID: 30808634
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
Front Immunol; 2021; 12():745320. PubMed ID: 34712233
[TBL] [Abstract][Full Text] [Related]
3. Systematic Evaluation of Neurotoxicity in Children and Young Adults Undergoing CD22 Chimeric Antigen Receptor T-Cell Therapy.
Shalabi H; Wolters PL; Martin S; Toledo-Tamula MA; Roderick MC; Struemph K; Kane E; Yates B; Delbrook C; Mackall CL; Lee DW; Fry TJ; Shah NN
J Immunother; 2018 Sep; 41(7):350-358. PubMed ID: 30048343
[TBL] [Abstract][Full Text] [Related]
4. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
5. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
6. Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Karschnia P; Arrillaga-Romany IC; Eichler A; Forst DA; Gerstner E; Jordan JT; Ly I; Plotkin SR; Wang N; Martinez-Lage M; Winter SF; Tonn JC; Rejeski K; von Baumgarten L; Cahill DP; Nahed BV; Shankar GM; Abramson JS; Barnes JA; El-Jawahri A; Hochberg EP; Johnson PC; Soumerai JD; Takvorian RW; Chen YB; Frigault MJ; Dietrich J
Neuro Oncol; 2023 Dec; 25(12):2239-2249. PubMed ID: 37402650
[TBL] [Abstract][Full Text] [Related]
7. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
Gauthier J; Turtle CJ
Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
[TBL] [Abstract][Full Text] [Related]
8. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
9. Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.
Hay KA
Br J Haematol; 2018 Nov; 183(3):364-374. PubMed ID: 30407609
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study.
Azoulay É; Castro P; Maamar A; Metaxa V; de Moraes AG; Voigt L; Wallet F; Klouche K; Picard M; Moreau AS; Van De Louw A; Seguin A; Mokart D; Chawla S; Leroy J; Böll B; Issa N; Levy B; Hemelaar P; Fernandez S; Munshi L; Bauer P; Schellongowski P; Joannidis M; Moreno-Gonzalez G; Galstian G; Darmon M; Valade S;
Lancet Haematol; 2021 May; 8(5):e355-e364. PubMed ID: 33894170
[TBL] [Abstract][Full Text] [Related]
11. Description of neurotoxicity in a series of patients treated with CAR T-cell therapy.
Belin C; Devic P; Ayrignac X; Dos Santos A; Paix A; Sirven-Villaros L; Simard C; Lamure S; Gastinne T; Ursu R; Berger C; Platon L; Tessoulin B; Azoulay E; Wallet F; Thieblemont C; Bachy E; Cartron G; Laplaud DA; Carpentier AF
Sci Rep; 2020 Nov; 10(1):18997. PubMed ID: 33149178
[TBL] [Abstract][Full Text] [Related]
12. CAR-T Cell Therapy-Related Neurotoxicity in Pediatric Acute Lymphoblastic Leukemia: Spectrum of Imaging Findings.
Tan AP
Pediatr Neurol; 2020 Oct; 111():51-58. PubMed ID: 32951662
[TBL] [Abstract][Full Text] [Related]
13. Clinical Outcomes and Toxicity in Older Adults Receiving Chimeric Antigen Receptor T Cell Therapy.
Johnson PC; Neckermann I; Sadrzadeh H; Newcomb R; El-Jawahri AR; Frigault MJ
Transplant Cell Ther; 2024 May; 30(5):490-499. PubMed ID: 38412928
[TBL] [Abstract][Full Text] [Related]
14. Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy.
Rubin DB; Al Jarrah A; Li K; LaRose S; Monk AD; Ali AB; Spendley LN; Nikiforow S; Jacobson C; Vaitkevicius H
JAMA Neurol; 2020 Dec; 77(12):1536-1542. PubMed ID: 32777012
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
[TBL] [Abstract][Full Text] [Related]
16. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
Chou CK; Turtle CJ
Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
[No Abstract] [Full Text] [Related]
17. Critical care management of chimeric antigen receptor T-cell therapy recipients.
Shimabukuro-Vornhagen A; Böll B; Schellongowski P; Valade S; Metaxa V; Azoulay E; von Bergwelt-Baildon M
CA Cancer J Clin; 2022 Jan; 72(1):78-93. PubMed ID: 34613616
[TBL] [Abstract][Full Text] [Related]
18. CAR T-cell therapy-related neurotoxicity in paediatric acute lymphocytic leukaemia.
Tan AP
Pediatr Blood Cancer; 2020 Nov; 67(11):e28635. PubMed ID: 32770654
[TBL] [Abstract][Full Text] [Related]
19. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
20. Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy.
Ruark J; Mullane E; Cleary N; Cordeiro A; Bezerra ED; Wu V; Voutsinas J; Shaw BE; Flynn KE; Lee SJ; Turtle CJ; Maloney DG; Fann JR; Bar M
Biol Blood Marrow Transplant; 2020 Jan; 26(1):34-43. PubMed ID: 31605820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
